Compare Genuine Parts Company (GPC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Viatris Inc — how do they compare? Genuine Parts Company trades at $135.22 (market cap $18.62B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Genuine Parts Company and Viatris Inc are close in size by market cap, and Genuine Parts Company pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| GPC | VTRS | |
|---|---|---|
Market Cap | $18.62B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $17.86 |
52-Week Low | $92.47 | $9.49 |
Enterprise Value | $24.72B | $30.80B |
Dividend Yield | 3.15% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
